1. Life Sciences Vision, Department for Business, Energy and Industrial Strategy, Department of Science, Innovation and Technology, Office for Life Sciences. Policy paper: Life sciences Vision. Jul 2021. https://www.gov.uk/government/publications/life-sciences-vision/life-sciences-vision-htm
2. Cohen D, McCartney M. Inclisiran: the “extremely unusual” political influence behind the novel drug’s approval. Pharmaceutical Journal. Dec 2023. https://pharmaceutical-journal.com/article/feature/inclisiran-the-influence-behind-the-novel-drugs-approval
3. Department of Health and Social Care, Department for International Trade, NHS England, Office for Life Sciences. New heart disease drug to be made available for NHS patients. Jan 2020. https://www.gov.uk/government/news/new-heart-disease-drug-to-be-made-available-for-nhs-patients
4. National Institute for Health and Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. 2021. Technology appraisal guidance. https://www.nice.org.uk/guidance/ta733
5. NHS England. NHS cholesterol-busting jab to save thousands of lives. Sep 2021. https://www.england.nhs.uk/2021/09/nhs-cholesterol-busting-jab-to-save-thousands-of-lives